Allison covers what scorching startups are getting as much as, and who’s financing them. She can also be co-host of the weekly biotech podcast, “The Readout Loud.” You may attain Allison on Sign at AllisonDeAngelis.01.
Elaine’s tales discover the growth in new weight problems remedies, new drug fee fashions, the methods corporations are affected by FDA adjustments, and the rising psychedelics drug sector. She co-writes The Readout publication, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You may attain Elaine on Sign at elaineywchen.70.
Adam Feuerstein is a senior author and biotech columnist, reporting on the crossroads of drug growth, enterprise, Wall Avenue, and biotechnology. He’s additionally a co-host of the weekly biotech podcast The Readout Loud and creator of the publication Adam’s Biotech Scorecard. You may attain Adam on Sign at stataf.54.
Can any of the brand new weight problems drugs in growth stand out from the pack? Which firm simply broke information with its IPO? And can the Meals and Drug Administration permit higher entry to experimental peptides?
We focus on all that and extra on this week’s episode of “The Readout LOUD,” STAT’s biotech podcast.
Undark’s Sara Talpos joins the podcast to debate her reporting on the peptide BPC-157, and the way it’s jumped from a Croatian lab to bodybuilding boards on Reddit to the FDA. (STAT co-published Talpos’ articles; the second piece was supported by the Pulitzer Middle). We additionally focus on the most recent information within the life sciences, together with weight problems information from the American Diabetes Affiliation assembly and a record-breaking IPO.
STAT+ Unique Story
Have already got an account? Log in
This text is unique to STAT+ subscribers
Unlock this text — plus in-depth evaluation, newsletters, premium occasions, and information alerts.
Have already got an account? Log in
Particular person plans
Group plans
View All Plans
To learn the remainder of this story subscribe to STAT+.
Subscribe
